These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. Wason JM; Mander AP; Eisen TG Eur J Cancer; 2011 May; 47(7):983-9. PubMed ID: 21239164 [TBL] [Abstract][Full Text] [Related]
25. Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. Mander AP; Wason JM; Sweeting MJ; Thompson SG Pharm Stat; 2012; 11(2):91-6. PubMed ID: 22232071 [TBL] [Abstract][Full Text] [Related]
26. Optimal two-stage log-rank test for randomized phase II clinical trials. Kwak M; Jung SH J Biopharm Stat; 2017; 27(4):639-658. PubMed ID: 27050043 [TBL] [Abstract][Full Text] [Related]
27. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach. Cellamare M; Sambucini V Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805 [TBL] [Abstract][Full Text] [Related]
28. Graphical search for two-stage designs for phase II clinical trials. Jung SH; Carey M; Kim KM Control Clin Trials; 2001 Aug; 22(4):367-72. PubMed ID: 11514038 [TBL] [Abstract][Full Text] [Related]
29. Optimal adaptive two-stage designs for phase II cancer clinical trials. Englert S; Kieser M Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324 [TBL] [Abstract][Full Text] [Related]
30. Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test. Kwak M; Jung SH Stat Med; 2014 May; 33(12):2004-16. PubMed ID: 24338995 [TBL] [Abstract][Full Text] [Related]
31. [Research design for patient selection in clinical trials phase II]. Kramar A; Potvin D; Hill C Rev Epidemiol Sante Publique; 1996 Aug; 44(4):364-71. PubMed ID: 8927779 [TBL] [Abstract][Full Text] [Related]
32. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Mander AP; Thompson SG Contemp Clin Trials; 2010 Nov; 31(6):572-8. PubMed ID: 20678585 [TBL] [Abstract][Full Text] [Related]
33. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials. Zhang Y; Mietlowski W; Chen B; Wang Y J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854 [TBL] [Abstract][Full Text] [Related]
34. Optimal multistage designs for randomised clinical trials with continuous outcomes. Wason JM; Mander AP; Thompson SG Stat Med; 2012 Feb; 31(4):301-12. PubMed ID: 22139822 [TBL] [Abstract][Full Text] [Related]
35. Optimal adaptive two-stage designs for early phase II clinical trials. Shan G; Wilding GE; Hutson AD; Gerstenberger S Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165 [TBL] [Abstract][Full Text] [Related]
36. Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring. Ray HE; Rai SN Pharm Stat; 2012; 11(2):170-6. PubMed ID: 22232063 [TBL] [Abstract][Full Text] [Related]
37. Optimal designs for phase II clinical trials with heterogeneous patient populations. Liu L; Cao S; Jung SH J Biopharm Stat; 2023 Jan; 33(1):1-14. PubMed ID: 35793231 [TBL] [Abstract][Full Text] [Related]
38. Optimal two-stage designs for phase II clinical trials. Simon R Control Clin Trials; 1989 Mar; 10(1):1-10. PubMed ID: 2702835 [TBL] [Abstract][Full Text] [Related]
39. P-value calculation for multistage phase II cancer clinical trials. Jung SH; Owzar K; George SL; Lee T J Biopharm Stat; 2006; 16(6):765-75; discussion 777-83. PubMed ID: 17146978 [TBL] [Abstract][Full Text] [Related]